1. Home
  2. POAI vs ENSC Comparison

POAI vs ENSC Comparison

Compare POAI & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POAI
  • ENSC
  • Stock Information
  • Founded
  • POAI 2002
  • ENSC 2003
  • Country
  • POAI United States
  • ENSC United States
  • Employees
  • POAI N/A
  • ENSC N/A
  • Industry
  • POAI Industrial Specialties
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • POAI Health Care
  • ENSC Health Care
  • Exchange
  • POAI Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • POAI 9.7M
  • ENSC 7.9M
  • IPO Year
  • POAI N/A
  • ENSC N/A
  • Fundamental
  • Price
  • POAI $1.50
  • ENSC $5.69
  • Analyst Decision
  • POAI Hold
  • ENSC
  • Analyst Count
  • POAI 1
  • ENSC 0
  • Target Price
  • POAI N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • POAI 2.9M
  • ENSC 52.1K
  • Earning Date
  • POAI 03-27-2025
  • ENSC 03-14-2025
  • Dividend Yield
  • POAI N/A
  • ENSC N/A
  • EPS Growth
  • POAI N/A
  • ENSC N/A
  • EPS
  • POAI N/A
  • ENSC N/A
  • Revenue
  • POAI $1,484,223.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • POAI N/A
  • ENSC $89.78
  • Revenue Next Year
  • POAI $569.48
  • ENSC N/A
  • P/E Ratio
  • POAI N/A
  • ENSC N/A
  • Revenue Growth
  • POAI N/A
  • ENSC 40.41
  • 52 Week Low
  • POAI $0.55
  • ENSC $2.12
  • 52 Week High
  • POAI $3.76
  • ENSC $14.85
  • Technical
  • Relative Strength Index (RSI)
  • POAI 53.98
  • ENSC 41.25
  • Support Level
  • POAI $1.37
  • ENSC $5.69
  • Resistance Level
  • POAI $1.97
  • ENSC $6.19
  • Average True Range (ATR)
  • POAI 0.15
  • ENSC 0.43
  • MACD
  • POAI 0.01
  • ENSC -0.02
  • Stochastic Oscillator
  • POAI 30.60
  • ENSC 32.79

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: